Andersen MD, Smereck GA, Hockman EM, Ross DJ, Ground KJ Nurses decrease barriers to health care by "hyperlinking" multiple-diagnosed women living with HIV/AIDS into care. J Assoc Nurses AIDS Care. 1999 Mar-Apr;10(2):55-65. doi: 10.1016/S1055-3290(06)60299-9.
Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9.
Campbell MK, Fayers PM, Grimshaw JM Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clin Trials. 2005;2(2):99-107. doi: 10.1191/1740774505cn071oa.
Campbell MK, Mollison J, Grimshaw JM Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Stat Med. 2001 Feb 15;20(3):391-9. doi: 10.1002/1097-0258(20010215)20:33.0.co;2-z.
Cramm JM, Finkenflugel HJ, Moller V, Nieboer AP TB treatment initiation and adherence in a South African community influenced more by perceptions than by knowledge of tuberculosis. BMC Public Health. 2010 Feb 17;10:72. doi: 10.1186/1471-2458-10-72.
Department of Health Management of Drug Resistant Tuberculosis: Policy Guidelines. i-151. 8-1-2012.
Department of Health National Strategic Plan on HIV, STIs and TB (2012-2016). 1-78. 12-1-2012.
Department of Labour The shortage of Medical Doctors in South Africa: Scarce and critical skills research project. 1-30-2009.
Dheda K, Lampe FC, Johnson MA, Lipman MC Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004 Nov 1;190(9):1670-6. doi: 10.1086/424676. Epub 2004 Sep 29.
Dumas JE, Lynch AM, Laughlin JE, Phillips Smith E, Prinz RJ Promoting intervention fidelity. Conceptual issues, methods, and preliminary results from the EARLY ALLIANCE prevention trial. Am J Prev Med. 2001 Jan;20(1 Suppl):38-47. doi: 10.1016/s0749-3797(00)00272-5.
Farley JE, Alwood K, Davis JG, Stellenberg E, and van der Walt M Development and Pilot Testing of MDR-TB/HIV In-Service Training in Rural KwaZulu Natal. National Education Association and Foundation of Nursing University Deans of South Africa Annual Conference . 10-15-2010.
Gardam M, Verma G, Campbell A, Wang J, Khan K Impact of the patient-provider relationship on the survival of foreign born outpatients with tuberculosis. J Immigr Minor Health. 2009 Dec;11(6):437-45. doi: 10.1007/s10903-008-9221-8. Epub 2009 Jan 6.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
Hsieh CJ, Lin LC, Kuo BI, Chiang CH, Su WJ, Shih JF Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary tuberculosis. J Clin Nurs. 2008 Apr;17(7):869-75. doi: 10.1111/j.1365-2702.2006.01924.x.
Institute of Healthcare Improvement Improving HIV Care: A Modular Quality Improvement Curriculum. Institue of Healthcare Improvemnet . 6-15-2011.
Iseman MD Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy. 1999;45 Suppl 2:34-40. doi: 10.1159/000048480.
Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9;4(9):e6914. doi: 10.1371/journal.pone.0006914.
Kliiman K, Altraja A Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010 Apr;14(4):454-63.
Lin RL, Lin FJ, Wu CL, Peng MJ, Chen PJ, Kuo HT Effect of a hospital-based case management approach on treatment outcome of patients with tuberculosis. J Formos Med Assoc. 2006 Aug;105(8):636-44. doi: 10.1016/S0929-6646(09)60162-5.
Roberts C, Roberts SA Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials. 2005;2(2):152-62. doi: 10.1191/1740774505cn076oa.
Schumann A, Nyamathi A, Stein JA HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults. J Health Psychol. 2007 Sep;12(5):833-43. doi: 10.1177/1359105307080618.
Welch G, Garb J, Zagarins S, Lendel I, Gabbay RA Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. Diabetes Res Clin Pract. 2010 Apr;88(1):1-6. doi: 10.1016/j.diabres.2009.12.026. Epub 2010 Feb 8.
Weyer K, Brand J, Lancaster J, Levin J, van der Walt M Determinants of multidrug-resistant tuberculosis in South Africa: results from a national survey. S Afr Med J. 2007 Nov;97(11 Pt 3):1120-8. No abstract available.
World Health Organization Global Tuberculosis Control. WHO/HTM/TB/2010.7. 2010. Geneva, Switzerland.
World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. [WHO/HTM/TB/2010.3]. 2010. World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, WHO Press.
Zeger SL, Liang KY Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986 Mar;42(1):121-30.
A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.